Phase 3 Post-essential Thrombocythemia Myelofibrosis Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled13 locationsNCT07357727
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
MyelofibrosisPolycythemia VeraPrimary Myelofibrosis+3 more
Merck Sharp & Dohme LLC400 enrolled21 locationsNCT06351631
Recruiting
Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734